ArticleBMC pregnancy and childbirth2025
Differential effects of type 2 diabetes and gestational diabetes on maternal and cord blood adipokines and newborn weight.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Umbilical cord asprosin and subfatin levels in relation to neonatal metabolic outcomes in gestational diabetes mellitus: a cross-sectional study.BMC endocrine disorders · 2026Article
- Gestational diabetes mellitus-induced adipokine dysregulation and links to metabolic programming risks.Frontiers in endocrinology · 2026Observational
- In-utero exposure to maternal diabetes and DNA methylation alterations in the Next Generation birth cohort.Clinical epigenetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDysregulated adipokine levels are associated with type 2 diabetes and gestational diabetes. Adiponectin and leptin are involved in nutrient transport, thereby affecting fetal growth and metabolism. We aimed to determine whether type 2 diabetes and gestational diabetes were associated different levels of serum and cord blood adiponectin, leptin, insulin and offspring birthweight.
methodsSerum, cord blood, gestational age and birthweight were collected for First Nations mothers and infants who were enrolled in the Next Generation Cohort Study. A total of 173 maternal and 188 neonatal samples were available for analysis. Of those, 136 were matched maternal infant dyads that we used for paired mother-infant analyses. Pairs were sorted into groups based on maternal diagnoses of pre-existing type 2 diabetes, gestational diabetes or no diabetes (control). Adiponectin and leptin were measured by enzyme linked immunosorbent assay.
resultsMothers with gestational diabetes had lower serum adiponectin (6.48 ± 3.64 µg/mL) in the third trimester relative to mothers with type 2 diabetes (8.55 ± 5.24 µg/mL, p < 0.05) or no diabetes (7.73 ± 3.47 µg/mL). However, cord blood adiponectin was lower only in normal weight pregnancies complicated by type 2 diabetes. Cord blood glucose, insulin and leptin were increased in infants of type 2 diabetes mothers and increased leptin was positively correlated with maternal leptin and birth weight. Female infants exposed to pregestational type 2 diabetes had a significantly higher birthweight z-score than female control infants.
conclusionsIn this study, exposure to type 2 diabetes, but not gestational diabetes, impacted cord blood levels of glucose, insulin and leptin and birthweight. Collectively, these factors may contribute to the greater impact of pregestational type 2 diabetes exposure on offspring health relative to gestational diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.